The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Belumosudil in Japanese patients with cGvHD: Results from a phase III trial
|
Results from a phase III trial of belumosudil as a second or subsequent line of therapy in Japanese patients aged ≥12 years with steroid-dependent/resistant chronic graft-versus-host disease (cGvHD) were presented during the European Hematology Association (EHA) 2024 Hybrid Congress by Onishi.1 This analysis evaluated the safety and efficacy of belumosudil at 48 weeks after the last patient enrolment.1 |
| Key learnings: |
|
The best overall response rates at 24 weeks (primary efficacy endpoint) and 48 weeks after last patient enrolment were both 85.7%. |
|
The median duration of response was 68.1 weeks, and the median failure-free survival and overall survival were not reached. |
|
No new safety concerns were observed, and there were no drug-related discontinuations or deaths. |
|
The high response rates and tolerable safety profile demonstrated in this trial support the use of belumosudil as a second or subsequent line of therapy in the treatment of Japanese patients aged ≥12 years with steroid-dependent/resistant cGvHD. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
